Skip to main content
Equibles
BBNX logo

BBNX · Beta Bionics, Inc. · Webcasts, Transcripts & Audio

Track BBNX — free

Use BBNX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBNX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.88 -3.52 (-16.43%) Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$962.33M
Shares
54.37M
Volume · Oct 28 1.22M Avg daily vol (3M) 1.31M

Beta Bionics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Beta Bionics, Inc. (BBNX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-27
Beta Bionics, Inc. (BBNX) Q3 2026 Earnings Call
Revenue
$35.51M
▲ 30.3% YoY
Diluted EPS
$-0.52
Gross margin
57.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-07-29
Beta Bionics, Inc. (BBNX) Q2 2026 Earnings Call
Revenue
$32.01M
▲ 37.8% YoY
Diluted EPS
$-0.53
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-04-21
Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
Confident tone Revenue growth and new patient starts Gross margin improvement Full-year 2026 guidance raise
Revenue
$27.63M
▲ 56.6% YoY
Diluted EPS
$-0.49
Gross margin
59.5%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-17
Beta Bionics, Inc. (BBNX) Q4 2025 Earnings Call Transcript
Confident tone 2026 guidance and outlook Pharmacy channel strategy User growth and installed base
Revenue
$32.12M*
▲ 57.1% YoY
Gross margin
59.0%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Beta Bionics, Inc. (BBNX) Q3 2025 Earnings Call Transcript
Confident tone iLet commercial momentum FDA 483 / MAUDE reports Innovation pipeline (Mint and bihormonal)
Revenue
$27.25M
▲ 63.1% YoY
Diluted EPS
$-0.33
Gross margin
55.5%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-29
Beta Bionics, Inc. (BBNX) Q2 2025 Earnings Call Transcript
Confident tone Pharmacy Channel Adoption iLet Product & Real-World Clinical Data Innovation Pipeline (Mint & Bihormonal)
Revenue
$23.24M
▲ 54.4% YoY
Diluted EPS
$-0.39
Gross margin
53.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Beta Bionics, Inc. (BBNX) Q1 2025 Earnings Call Transcript
Confident tone Q1 financial outperformance and raised 2025 guidance iLet product differentiation and algorithm Gross margin dynamics and near-term headwinds
Revenue
$17.64M
▲ 36.4% YoY
Diluted EPS
$-0.93
Gross margin
50.9%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Beta Bionics, Inc. (BBNX) Q4 2024 Earnings Call
Revenue
$20.44M*
Gross margin
57.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–8 of 8 webcasts
Key facts CIK 1674632 CUSIP 08659B102 13F (30d) 22 filings 22 filers Visit website Investor relations